Back to Search
Start Over
Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed?
- Source :
- Urologic Clinics of North America. 44:611-621
- Publication Year :
- 2017
- Publisher :
- Elsevier BV, 2017.
-
Abstract
- Androgen deprivation therapy (ADT) has been conventional treatment of newly diagnosed metastatic prostate cancer for more than 70 years. However, all patients eventually become castration-resistant and a significant proportion of life span is spent in the castration-resistant state. Prospective randomized control trials have incorporated early chemotherapy along with ADT based on the hypothesis that a significant level of resistance to ADT already exists in newly diagnosed metastatic prostate cancer and ADT exhibits synergistic antitumor activity with taxanes. In this chapter we discuss the changing landscape of management of newly diagnosed metastatic prostate cancer patients based on recently published landmark randomized trials.
- Subjects :
- Male
0301 basic medicine
Oncology
medicine.medical_specialty
Antineoplastic Agents, Hormonal
Urology
medicine.medical_treatment
Newly diagnosed
Article
law.invention
Androgen deprivation therapy
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Randomized controlled trial
law
Internal medicine
Humans
Medicine
Neoplasm Metastasis
Antitumor activity
Chemotherapy
business.industry
Conventional treatment
Prostatic Neoplasms
medicine.disease
030104 developmental biology
Docetaxel
030220 oncology & carcinogenesis
business
medicine.drug
Subjects
Details
- ISSN :
- 00940143
- Volume :
- 44
- Database :
- OpenAIRE
- Journal :
- Urologic Clinics of North America
- Accession number :
- edsair.doi.dedup.....8146f185874eff9cc9dafef2b10a4ab3